Natalie G. Ahn

Natalie G. Ahn

Auto-generated profile, based on publicly available information

Natalie G. Ahn

Department of Biochemistry, University of Colorado

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2005 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
WOWilliam M. Old
William M. Old
KMKaren Meyer-Arendt
Karen Meyer-Arendt
LALauren Aveline-Wolf
Lauren Aveline-Wolf
KPKevin G. Pierce
Kevin G. Pierce
AMAlex Mendoza
Alex Mendoza
NANatalie G. Ahn
Natalie G. Ahn
The bronchodilator potencies of inhaled atropine sulphate and atropine methonitrate have been compared either alone or in combination with fenoterol in a group of adult asthmatic patients. A cumulative dose response study showed that 2 mg of atropine sulphate produced near maximum bronchodilatation. A larger dose of 4 mg was used in comparing the potency of this drug with 2 mg of atropine methonitrate, a dose previously shown to produce optimum bronchodilatation. In a randomised double-blind fashion atropine methonitrate (2 mg), atropine sulphate (4 mg), fenoterol (400 μg), a combination of atropine methonitrate with fenoterol, a combination of atropine sulphate with fenoterol, and two placebos were administered by inhalation on separate days to eight stable adult asthmatics. Measurements of FEV1 were made before administration of the drugs and at 20 minutes, one, two, four, and six hours afterwards. The two atropine drugs produced a similar peak effect but the bronchodilatation after atropine methonitrate was more prolonged. In combination the bronchodilatation achieved with both atropine drugs and fenoterol was greater than with either atropine or fenoterol alone, confirming that atropine and an adrenergic drug can have an additive effect. The response with atropine methonitrate and fenoterol showed a significant increase in the FEV1 for six hours whereas with atropine sulphate and fenoterol the increase of FEV1 was significantly greater than the placebo for only four hours. It was concluded that the atropine drugs produce useful bronchodilatation either alone or in combination with an adrenergic agent. Of the two atropine drugs, the methonitrate appears to be superior to the sulphate as an inhaled bronchodilator in adult asthmatics.

1 April 2004 in Molecular Cell
Verified
Journal Article
Closed access
TLThomas Lee
Thomas Lee
AHAndrew N Hoofnagle
Andrew N Hoofnagle
YKYukihito Kabuyama
Yukihito Kabuyama
JSJames Stroud
James Stroud
XMXiaoshan Min
Xiaoshan Min
NANatalie G Ahn
Natalie G Ahn

18 April 2008 in Science
Verified
Journal Article
Closed access
PDF file
EWEric S. Witze
Eric S. Witze
ELElizabeth S. Litman
Elizabeth S. Litman
GAGretchen M. Argast
Gretchen M. Argast
RMRandall T. Moon
Randall T. Moon
NANatalie G. Ahn
Natalie G. Ahn
Mechanisms by which Wnt pathways integrate the organization of receptors, organelles, and cytoskeletal proteins to confer cell polarity and directional cell movement are incompletely understood. We show that acute responses to Wnt5a involve recruitment of actin, myosin IIB, Frizzled 3, and melanoma cell adhesion molecule into an intracellular structure in a melanoma cell line. In the presence of a chemokine gradient, this Wnt-mediated receptor–actin–myosin polarity (W-RAMP) structure accumulates asymmetrically at the cell periphery, where it triggers membrane contractility and nuclear movement in the direction of membrane retraction. The process requires endosome trafficking, is associated with multivesicular bodies, and is regulated by Wnt5a through the small guanosine triphosphatases Rab4 and RhoB. Thus, cell-autonomous mechanisms allow Wnt5a to control cell orientation, polarity, and directional movement in response to positional cues from chemokine gradients.

11 August 2017 in Science
Verified
Journal Article
Closed access
PDF file
FMFrancesca Mattiroli
Francesca Mattiroli
SBSudipta Bhattacharyya
Sudipta Bhattacharyya
PDPamela N. Dyer
Pamela N. Dyer
AWAlison E. White
Alison E. White
KSKathleen Sandman
Kathleen Sandman
KLKarolin Luger
Karolin Luger
Origin of DNA compaction: As a repeating unit in eukaryotic chromatin, a nucleosome wraps DNA in superhelical turns around a histone octamer. Mattiroli et al. present the crystal structure of an archaeal histone-DNA complex in which the histone-mediated DNA geometry is exactly the same as that in the nucleosome. Comparing features of archaeal and eukaryotic chromatin structures offers important insights into the evolution of eukaryotic nucleosomes. Science , this issue p. 609

1 April 2009 in Molecular Cell
Verified
Journal Article
Closed access
WOWilliam M. Old
William M. Old
JSJohn B. Shabb
John B. Shabb
SHStephane Houel
Stephane Houel
HWHong Wang
Hong Wang
KCKasey L. Couts
Kasey L. Couts
NANatalie G. Ahn
Natalie G. Ahn

1 June 2015 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
SSScott A. Stuart
Scott A. Stuart
SHStephane Houel
Stephane Houel
TLThomas Lee
Thomas Lee
NWNan Wang
Nan Wang
WOWilliam M. Old
William M. Old
NANatalie G. Ahn
Natalie G. Ahn
Inhibitors of oncogenic B-RAFV600E and MKK1/2 have yielded remarkable responses in B-RAFV600E-positive melanoma patients. However, the efficacy of these inhibitors is limited by the inevitable onset of resistance. Despite the fact that these inhibitors target the same pathway, combination treatment with B-RAFV600E and MKK1/2 inhibitors has been shown to improve both response rates and progression-free survival in B-RAFV600E melanoma patients. To provide insight into the molecular nature of the combinatorial response, we used quantitative mass spectrometry to characterize the inhibitor-dependent phosphoproteome of human melanoma cells treated with the B-RAFV600E inhibitor PLX4032 (vemurafenib) or the MKK1/2 inhibitor AZD6244 (selumetinib). In three replicate experiments, we quantified changes at a total of 23,986 phosphosites on 4784 proteins. This included 1317 phosphosites that reproducibly decreased in response to at least one inhibitor. Phosphosites that responded to both inhibitors grouped into networks that included the nuclear pore complex, growth factor signaling, and transcriptional regulators. Although the majority of phosphosites were responsive to both inhibitors, we identified 16 sites that decreased only in response to PLX4032, suggesting rare instances where oncogenic B-RAF signaling occurs in an MKK1/2-independent manner. Only two phosphosites were identified that appeared to be uniquely responsive to AZD6244. When cells were treated with the combination of AZD6244 and PLX4032 at subsaturating concentrations (30 nm), responses at nearly all phosphosites were additive. We conclude that AZD6244 does not substantially widen the range of phosphosites inhibited by PLX4032 and that the benefit of the drug combination is best explained by their additive effects on suppressing ERK1/2 signaling. Comparison of our results to another recent ERK1/2 phosphoproteomics study revealed a surprising degree of variability in the sensitivity of phosphosites to MKK1/2 inhibitors in human cell lines, revealing unexpected cell specificity in the molecular responses to pathway activation.